​Carestream Health will show a model of its cone beam CT (CBCT) system at AHRA that is currently undergoing clinical studies and is being designed to: provide weight-bearing images of knees, legs and feet as well as other orthopaedic exams; use less radiation than traditional CT; and be used in a wide range of facilities. This CBCT system is INVESTIGATIONAL and NOT AVAILABLE FOR COMMERCIAL SALE. Carestream is also demonstrating its new Touch Ultrasound platform that received 510(k) Clearance and is available for sale in the United States and its advanced healthcare IT solutions including PACS, vendor-neutral archive, Clinical Collaboration Platform and Carestream’s Vue Motion enterprise viewer.

Together with its customers, Elekta raised EUR 30,575 (USD 33,250) during the 3rd European Society for Therapeutic Radiology and Oncology (ESTRO) Forum in Barcelona in April. The funds will be donated to Radiating Hope, a nonprofit organization with the mission to improve cancer care, specifically radiation oncology care, around the world.

Four studies evaluating effectiveness, trends and other considerations for active surveillance in managing prostate cancer were presented during the 110th annual scientific meeting of the American Urological Association (AUA). Stacy Loeb, M.D., assistant professor of urology at New York University, moderated the session.

The prostate-specific membrane antigen (PSMA) biomarker is the bullseye for three new magnetic resonance imaging (MRI) agents that bind to the protein in not only prostate cancer, but a range of tumor types. The agents were discussed in research unveiled at the 2015 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

Researchers announced the results of a study to develop and validate a model, comprised of echocardiographic and clinical data, to predict three-year mortality of patients hospitalized in coronary care units (CCU). The results describe an integrated score for three-year mortality of CCU patients, comprised of fewer variables and better/equal predictive value compared to existing scores.

Researchers announced results of a new study which demonstrated that smartphone-based mHealth devices, coupled with handheld echocardiography, can provide improved assessment and are readily integrated at the point-of-care for evaluation of patients with structural heart diseases. This study was conducted as part of the American Society of Echocardiography (ASE) Foundation’s Valvular Assessment Leading to Unexplored Echocardiographic Stratagems (VALUES) program, a four-day teaching and research event held at the Sri Sathya Sai Institute of Higher Medical Sciences in Bangalore, India, August 11-14, 2014. Over the course of several days, researchers assessed patients with multiple forms of rheumatic valvular heart disease with either standard diagnostic equipment or mobile health-based devices.

A first-in-human study shows how a powerful new drug finds and attaches itself to the ovarian and prostate cancer cells for both imaging and personalized cancer treatment. Study results were revealed at the 2015 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

Siemens’ PETNET Solutions Inc. has entered into a nationwide agreement with U.K.-based Blue Earth Diagnostics Ltd. for the exclusive commercial manufacturing and distribution of Fluciclovine (18F), an investigational positron emission tomography and computed tomography (PET/CT) radiopharmaceutical. Fluciclovine (18F) is being studied for prostate imaging in clinical trials conducted in the United States, Japan, Italy, Norway, Sweden and Finland. The F-18-based radiopharmaceutical has a long half-life, which may facilitate its geographical distribution to clinical trial sites and then to clinical imaging centers once it gains approval from the U.S. Food and Drug Administration (FDA).